- presence of measurable, metastatic non-small cell lung cancer (histologically or
cytologically confirmed at the time of original diagnosis)
- treatment failure (recurrence, disease progression, or intolerable toxicity) of 2 or 3
prior systemic treatments. (Note: no more than 3 prior systemic regimens for non-small
cell lung cancer including adjuvant chemotherapy)
- capable of understanding the nature of the trial and willing to give written informed
consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
- hemoglobin level of >=9 g/dL, absolute granulocyte count of >=1.5 × 109/L, and
platelet count of >=100 × 109/L
- adequate renal function, as documented by a serum creatinine level of
institutional upper limit of normal (ULN) and a measured or calculated creatinine
clearance of >=60 mL/min
- adequate liver function, as demonstrated by a total bilirubin level of
ULN; levels of serum glutamate oxaloacetic transaminase (SGOT) (aspartate
aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine
aminotransferase [ALT])
and ALT should be
- for men with partners of child-bearing potential and all women of childbearing
potential, willingness to use adequate contraception or practice abstinence during the
course of the study at least 18 years of age
- life expectancy estimated at greater than 12 weeks
- history of blood transfusion within the last 14 days
- need of concurrent administration of allopurinol
- history of radiotherapy or chemotherapy within 4 weeks (nitrosourea or mitomycin C
within 6 weeks) of the anticipated first day of dosing (patient must be fully
recovered from the acute effects of any prior chemotherapy or radiotherapy)
- any psychological or sociological condition, addictive disorder, or family problems
that might preclude compliance with the protocol
- any unstable or severe intercurrent medical condition that in the opinion of the
investigator might interfere with achievement of study objectives
- receipt of an investigational agent within 28 days before the anticipated first day of
dosing (patient must have recovered from all acute effects of previously administered
investigational agents)
- pregnant or breast-feeding
- previous treatment with GARFT inhibitors
- history of radiation therapy to more than 40% of the marrow space
- history of a malignancy (other than non-small cell lung cancer) except those treated
with curative intent for skin cancer (other than melanoma) or in situ breast or
cervical cancer or those treated with curative intent for any other cancer with no
evidence of disease for 5 years
- active brain metastases (requiring treatment or progressing)